- Home
- KMDA vs RCKT Comparison
KMDA vs RCKT Comparison
Compare KMDA & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KMDA | RCKT |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | Israel | United States |
| Employees | N/A | 202 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.3M | 401.6M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | KMDA | RCKT |
|---|---|---|
| Price | $7.49 | $3.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $14.00 | ★ $29.73 |
| AVG Volume (30 Days) | 37.8K | ★ 3.0M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.94 | N/A |
| Revenue Next Year | $9.84 | $64.28 |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.50 | $2.53 |
| 52 Week High | $9.35 | $5.45 |
Technical Indicators
Market Signals| Indicator | KMDA | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 69.15 |
| Support Level | $7.35 | $3.32 |
| Resistance Level | $7.52 | $4.04 |
| Average True Range (ATR) | 0.14 | 0.21 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 68.49 | 98.21 |
Price Performance
Historical ComparisonAbout KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.